bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent β-Thalassaemia (TDT) at 24th European Haematology Association (EHA) Congress
bluebird bio Presents New Data for LentiGlobin® Gene Therapy for Sickle Cell Disease (SCD) at 24th European Haematology Association (EHA) Congress
Links to sites outside of this website are provided as a resource to the viewer. bluebird bio accepts no responsibility for the content of linked sites.